The adenosine deaminases acting on RNA (ADAR) enzymes catalyse conversion of adenosine to inosine in dsRNA. A positive effect of ADAR1 on human immunodeficiency virus type 1 (HIV-1) replication has recently been reported. Here, we show that another ADAR enzyme, ADAR2, positively affects the replication process of HIV-1. We found that, analogously to ADAR1, ADAR2 enhances the release of progeny virions by an editing-dependent mechanism. However, differently from the ADAR1 enzyme, ADAR2 does not increase the infectious potential of the virus. Importantly, downregulation of ADAR2 in Jurkat cells significantly impairs viral replication. Therefore, ADAR2 shares some but not all proviral functions of ADAR1. These results suggest a novel role of ADAR2 as a viral regulator.
Adenosine deaminases acting on RNA (ADARs) are RNAediting enzymes that catalyse the hydrolytic deamination of adenosine (A) to inosine (I) in dsRNA (Bass, 2002; Gott & Emeson, 2000; Nishikura, 2010) . Since inosines are recognized as guanosines by the translational (Basilio et al., 1962) and splicing (Rueter et al., 1999) machineries, the ADAR enzymes can alter mRNA codons and splice sites and give rise to a variety of different protein isoforms (Nishikura, 2006; Valente & Nishikura, 2005) . Three members of the ADAR family have been identified in vertebrates: ADAR1-3 (Bass, 2002; Keegan et al., 2001; Valente & Nishikura, 2005) . ADAR1 and ADAR2 are catalytically active enzymes expressed in several cells and tissues, while ADAR3 is a brain-specific protein for which RNA substrates have not yet been identified (Chen et al., 2000; Melcher et al., 1996) . Recently, dysfunctions of A-to-I RNA editing have been connected to several human pathologies, such as cancer or viral infections (Farajollahi & Maas, 2010; Gallo & Galardi, 2008; George et al., 2009) . We and others have previously reported that ADAR1 exerts a pro-viral effect during human immunodeficiency virus type 1 (HIV-1) replication (Clerzius et al., 2009; Doria et al., 2009; Phuphuakrat et al., 2008) . In particular, we showed that ADAR1 stimulates both the release and infectivity of viral particles by an editing-dependent mechanism (Doria et al., 2009) . Indeed, ADAR1-induced A-to-I changes have been identified in HIV-1 transcripts (Doria et al., 2009; Phuphuakrat et al., 2008) , although the functional consequences of such changes should still be determined. In the present study, we explored the role of ADAR2 in HIV-1 replication.
We first evaluated ADAR2 expression in HIV-1 cell targets as well as in 293T cells. To this aim, 40 mg of total cell lysates from freshly purified CD4 + T lymphocytes, Jurkat leukaemic T-cell line, U937 monocyte lymphoma cell line and 293T cells were analysed by Western blotting with antibodies anti-ADAR2 (K20; Santa Cruz) and anti-actin (AC-15; Sigma). We observed that, analogously to ADAR1 (Doria et al., 2009) , ADAR2 is expressed in HIV-1 T-cell targets but not in U937 cells (Fig. 1a) . Of note, 293T cells, commonly employed as HIV-1 producer cells, display low/ undetectable endogenous editing activity (Cenci et al., 2008; Dawson et al., 2004; Doria et al., 2009; Herb et al., 1996; Rueter et al., 1999) despite expressing both ADAR1 (Doria et al., 2009) and ADAR2 (Fig. 1a) enzymes.
To test whether ADAR2 affects the expression of HIV-1 proteins, we co-transfected 293T cells with 5 mg pNL4-3 proviral DNA (NIH reagent program) together with 3 mg of a vector expressing either the EGFP-tagged ADAR2, the mutant EGFP-ADAR2 E/A lacking the editing activity, an unrelated protein (EGFP-CTNS) or EGFP alone. All these plasmids have been previously described (Cenci et al., 2008; Doria et al., 2009) . Comparable transfection efficiency was confirmed by measuring the EGFP + cells percentage by flow cytometry. Compared to the endogenous ADAR2, EGFP-ADAR2 wild-type (wt) and mutant proteins showed the same nucleolar localization (Cenci et al., 2008; Desterro et al., 2003) and were expressed at about 10-fold higher levels (data not shown). Post-transfection (48 h), total cell extracts were analysed by Western blotting with antibodies against EGFP (mouse monoclonal; Clontech), tubulin (DH1A; Sigma), HIV-1 Nef protein (ARP444 obtained from NIBSC) and the total serum of an HIV-infected patient (Fig. 1b, c) . Notably, the EGFP-ADAR2 or the inactive EGFP-ADAR2 E/A proteins led to an increase of viral protein accumulation if compared with EGFP (Fig. 1b) or EGFP-CTNS controls (Fig. 1c) . Based on their apparent molecular masses, various viral proteins reacting with the anti-HIV-1 human serum are indicated in Fig. 1(b, c) . The signals corresponding to the gp120 Env product and p24 Gag capsid antigen were confirmed by means of specific antibodies (data not shown) and quantified together with Nef-specific signals by densitometric analysis in four independent experiments. Fig. 1(d) shows that the overexpression of ADAR2 active and inactive proteins increased the average levels of p24 by fourfold, but had a minor effect on gp120 and Nef proteins when compared to controls. Therefore, similar to ADAR1 (Doria et al., 2009) , ADAR2 enhances the expression of some HIV-1 viral proteins, such as p24, via an editing-independent mechanism, that needs to be investigated in future studies. The editing-independent capacity of ADAR2 may be contributed by an inhibitory effect of the enzyme on the dsRNA-activated protein kinase (PKR) that would otherwise shut-down protein synthesis by phosphorylating eIF-2a, as shown for ADAR1 (Doria et al., 2009) . Indeed, reduced levels of phosphorylated eIF-2a were found in cells expressing EGFP-ADAR2 wt or E/A (Fig. 1e) .
Next, we examined whether ADAR2 overexpression could affect the release of progeny virions. Transfected 293T cells expressing HIV-1 together with EGFP-tagged CTNS, ADAR1, ADAR2 or the inactive E/A variants of ADAR1 or ADAR2 were analysed for the presence of p24 in the cell culture medium by ELISA (Immunogenetics). The overexpression of both ADAR1 and ADAR2 increased the levels of p24 released in the cell medium up to sevenfold compared with the control (Fig. 1f , one representative experiment out of three performed in triplicate). Notably, the inactive ADAR E/A isoforms showed a smaller effect (up to threefold), despite the intracellular accumulation of p24 and its precursors were comparable to those observed in cells expressing the corresponding wt enzymes (Fig. 1c and data shown in Doria et al., 2009) . These data suggest that the multi-step process leading to the release of new HIV-1 particles is specifically stimulated by the editing activity of both ADAR1 and ADAR2.
To investigate whether ADAR2 could influence the infectious potential of HIV-1, as previously observed for ADAR1 (Doria et al., 2009 ), 293T cells were co-transfected with 15 mg of pNL4-3 together with 8 mg of either pEGFP, pEGFP-ADAR1, pEGFP-ADAR1 E/A, pEGFP-ADAR2 or pEGFP-ADAR2 E/A. After 48 h, the cell medium containing the virus was collected and an equal amount of virus was used for a single-round infection of CEM-GFP indicator cells (400 ng p24/5610 4 cells) (Doria et al., 2009) . As reported in Fig. 1(g, h) , the virus produced by EGFP-ADAR1 + cells exhibited a 2.5-fold higher infectious capacity if compared with control virus released by EGFP + cells. Conversely, the virus produced by the EGFP-ADAR2 + cells showed a modest not significant increase in infectivity. In addition, the infectious potential of HIV-1 produced in the presence of the deaminase-inactive enzymes did not differ significantly from that of the control virus. Therefore, although the editing activity of both ADAR2 and ADAR1 stimulates the release of HIV-1 particles, only the RNA editing due to ADAR1 results in an increased viral infectivity.
The different editing-dependent effects of ADAR1 and ADAR2 on HIV-1 particles could be explained by their distinct ability to recognize, bind and edit specific viral transcripts. Indeed, it has been shown that differences exist between ADAR enzymes as to their sequence preferences in RNA substrates (Bass, 2002; Lehmann & Bass, 2000; Ohman et al., 2000) . To test this hypothesis, the viral sequences previously shown to be targeted by ADAR1 were analysed for the ADAR2 editing activity using the same experimental approach (Doria et al., 2009) . Briefly, total RNA isolated from 293T cells expressing HIV-1 together with EGFP, EGFP-ADAR1 or EGFP-ADAR2 was subjected to reverse transcription to generate cDNA pools that were used as templates for the amplification of specific HIV-1 regions. Strikingly, we found that ADAR2 edits, although to different extents, the same adenosines modified by ADAR1 within the 59 UTR of viral transcripts, but not those adenosines within the Rev and Tat coding sequences (Fig. 2) . These results support the hypothesis that HIV-1 transcripts are edited by both ADAR enzymes, but differences exist between ADAR1 and ADAR2. Future work, implemented by deep-sequencing in cells specifically silenced for either ADAR1 or ADAR2, will allow the identification of all the editing events in HIV-1 transcripts mediated by the two enzymes. Additionally, site-specific mutagenesis will establish which editing events are important to stimulate specific steps of HIV-1 replication.
To confirm and further investigate the role played by ADAR2 as an HIV-1 proviral factor, we tested viral replication in Jurkat cells in which the expression of the enzyme was stably impaired. First, we selected stable polyclonal Jurkat cells in which we downregulated the endogenous ADAR2 protein level using the BLOCK-iT inducible Pol II miR RNAi Expression Vector kit with EmGFP (Invitrogen). Jurkat cells stably expressing siADAR2 or scramble primers (over 90 % GFP + , Fig. 3a) were analysed for ADAR2 expression by quantitative (q) RT-PCR and Western blotting (Fig. 3b, c) . The siADAR2 cells showed 50 % reduction at mRNA and protein levels as compared with the controls, while no differences were found in ADAR1 mRNA and protein expression ( Supplementary Fig.  S1a , b, available in JGV Online). Unspecific interferon-based effects did not occur upon silencing of ADAR2 as the levels of two interferon-inducible proteins, ADAR1 p150 and PKR (Samuel, 2001) , were unaffected in siADAR2 Jurkat cells ( Supplementary Fig. S1b, c) . The expression of CD4 and CXCR4 receptors did not differ among untreated (mock), scramble and siADAR2 Jurkat cells (data not shown). Equal numbers of mock, scramble and siADAR2 Jurkat cells were infected with NL4-3 virus (25 ng of p24 per 10 6 cells) and monitored for viral replication at different times by measuring p24 in the cell supernatants (Fig. 3d) . We found that HIV-1 replication was significantly impaired in Jurkat cells stably silenced for ADAR2 expression when compared with the control cells (70-80 % reduced p24 levels at day 10) (Fig. 3d) . Normal cell growth and maintenance of ADAR2 silencing were also monitored throughout the experiment ( Supplementary Fig. S1d, e) .
Overall, our results demonstrate that ADAR2 is a host factor that supports HIV-1 replication.
There is growing evidence suggesting a role for ADARs in the replication process of different viruses. In particular, ADAR1 has been demonstrated to exert either a proviral effect, as for hepatitis delta virus (HDV) (Jayan & Casey, 2002) , measles virus (MV) , vesicular stomatitis virus (VSV) (Nie et al., 2007) and HIV-1 (Clerzius et al., 2009; Doria et al., 2009; Phuphuakrat et al., 2008) , or an antiviral effect, as for hepatitis C virus (HCV) (Taylor et al., 2005) . These activities of ADAR1 can be editing-dependent (HDV and HCV), editing-independent (MV and VSV) or both (HIV-1).
The present work also demonstrates that ADAR2 can be a key player in HIV-1 infection and opens new questions as to whether this enzyme may act on the replication of other viruses. The importance of ADAR2 in HIV-1 replication disclosed herein could be contributed in vivo by the enzyme capacity to edit host transcripts involved in cellular processes important for the virus. Indeed, recent studies demonstrated that ADAR2 can inhibit cell proliferation (Cenci et al., 2008; Paz et al., 2007) and migration (Cenci et al., 2008) and thus may favour HIV-1 replication and spread in certain instances (Fackler et al., 2007) . In addition, ADAR2 was recently shown to stimulate exocytosis (Yang et al., 2010) , a pathway that viruses can hijack for efficient assembly and cell-to-cell spread (Morita & Sundquist, 2004) .
By providing further insight into the role of ADAR enzymes in sequence diversification and replication of The endogenous ADAR2 expression level was analysed by qRT-PCR (Taqman probe, ID Hs00953730_m1; Applied Biosystem) as described previously (Cenci et al., 2008) and Western blotting. The error bars represent SEM of two independent experiments. (d) Jurkat cell lines (mock, scramble and siADAR2) were infected in triplicate with HIV-1 by standard spin-infection method, then washed and seeded at 0.8¾10 6 cells ml "1 without blasticidin selection. Aliquots of cell supernatant were collected at various time points p.i. to measure p24 levels by ELISA in triplicates. One representative experiment out of three, with the relative SEM values, is shown.
ADAR2 is a novel HIV-1 proviral factor HIV-1, our study may help the discovery of novel potential targets for antiviral intervention.
